Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DurHope
NCT04945720Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Apr 2022; status: completed.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04945720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945720.